These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 28434649

  • 21. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
    Reig M, Matilla A, Bustamante J, Castells L, de La Mata M, Delgado M, Moreno JM, Forner A, Varela M.
    Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Long-term treatment of hepatocellular carcinoma with sorafenib.
    Rombolà F, Spinoso A.
    Infez Med; 2013 Jun; 21(2):167-8. PubMed ID: 23774984
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Field practice studies on sorafenib: lessons in systemic treatment of hepatocellular carcinoma.
    Piscaglia F, Salvatore V, Venerandi L.
    Dig Liver Dis; 2013 May; 45(5):367-8. PubMed ID: 23562444
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Sorafenib in advanced hepatocellular carcinoma.
    Spinzi G, Paggi S.
    N Engl J Med; 2008 Dec 04; 359(23):2497-8; author reply 2498-9. PubMed ID: 19052134
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Geschwind JF, Chapiro J.
    Clin Adv Hematol Oncol; 2016 Aug 04; 14(8):585-7. PubMed ID: 27487101
    [No Abstract] [Full Text] [Related]

  • 33. Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report.
    de Stefano G, Iodice V, Farella N.
    J Gastrointest Cancer; 2015 Dec 04; 46(4):430-3. PubMed ID: 25894635
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.
    Solms A, Reinecke I, Fiala-Buskies S, Keunecke A, Drenth HJ, Bruix J, Meinhardt G, Cleton A, Ploeger B.
    Eur J Pharm Sci; 2017 Nov 15; 109S():S149-S153. PubMed ID: 28549676
    [Abstract] [Full Text] [Related]

  • 38. New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies.
    Niu L, Liu L, Yang S, Ren J, Lai PBS, Chen GG.
    Biochim Biophys Acta Rev Cancer; 2017 Dec 15; 1868(2):564-570. PubMed ID: 29054475
    [Abstract] [Full Text] [Related]

  • 39. New knowledge of the mechanisms of sorafenib resistance in liver cancer.
    Zhu YJ, Zheng B, Wang HY, Chen L.
    Acta Pharmacol Sin; 2017 May 15; 38(5):614-622. PubMed ID: 28344323
    [Abstract] [Full Text] [Related]

  • 40. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
    Sacco R, Antonucci M, Bargellini I, Marceglia S, Mismas V, Cabibbo G.
    Future Oncol; 2015 May 15; 11(17):2371-3. PubMed ID: 26270206
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.